Valerio Therapeutics

Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on intracellular DNA-binding targets, we design and develop first-in-class treatments for oncology and inflammatory diseases...

Oncology,dna damage response,epigenetics,translational research,partnering,m&a,licensing,dna repair,hdac,cancer,oligonucleotide,ddr,and dna decoy

Valerio therapeutics operates in the Pharmaceutical manufacturing industry.

Valerio therapeutics's revenue is 1m - 10m

Valerio therapeutics has 51 - 200 employees.